<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-GMIHT2L6</identifier><date>2022</date><creator>Bolčina, Lara</creator><creator>Kos, Janko</creator><creator>Pišlar, Anja</creator><relation>documents/doc/G/URN_NBN_SI_doc-GMIHT2L6_001.pdf</relation><relation>documents/doc/G/URN_NBN_SI_doc-GMIHT2L6_001.txt</relation><format format_type="issue">5</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 403-409</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">132623619</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-GMIHT2L6</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Alzheimerjeva bolezen</subject><subject language_type_id="slv">cisteinski katepsini</subject><subject language_type_id="slv">nevrodegeneracija</subject><subject language_type_id="slv">Nevrodegenerativne bolezni</subject><subject language_type_id="slv">Parkinsonova bolezen</subject><subject language_type_id="slv">vnetni odziv</subject><title>Importance of cysteine peptidases in neurodegenerative disorders</title><title>Pomen cisteinskih peptidaz pri nevrodegenerativnih boleznih</title></Record>